{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:26:36Z","timestamp":1790731596031,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":44,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642335693","type":"print"},{"value":"9783642335709","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-3-642-33570-9_14","type":"book-chapter","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T12:31:22Z","timestamp":1355401882000},"page":"307-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Botulinum Toxin: Application, Safety, and Limitations"],"prefix":"10.1007","author":[{"given":"Hans","family":"Bigalke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,14]]},"reference":[{"issue":"23","key":"14_CR1","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.2174\/0929867043363802","volume":"11","author":"KR Aoki","year":"2004","unstructured":"Aoki KR (2004) Botulinum toxin: a successful therapeutic protein. Curr Med Chem 11(23):3085\u20133092","journal-title":"Curr Med Chem"},{"issue":"8","key":"14_CR2","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14656566.7.8.1085","volume":"7","author":"S Aurora","year":"2006","unstructured":"Aurora S (2006) Botulinum toxin type A for the treatment of migraine. Expert Opin Pharmacother 7(8):1085\u20131095","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"14_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.tox.2005.06.015","volume":"214","author":"H Bigalke","year":"2005","unstructured":"Bigalke H, Rummel A (2005) Medical aspects of toxin weapons. Toxicology 214(3):210\u2013220","journal-title":"Toxicology"},{"issue":"3","key":"14_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/BF00505657","volume":"316","author":"H Bigalke","year":"1981","unstructured":"Bigalke H, Heller I, Bizzini B, Habermann E (1981) Tetanus toxin and botulinum a toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol 316(3):244\u2013251","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/BF00343235","volume":"203","author":"W Birkmayer","year":"1962","unstructured":"Birkmayer W, Hornykiewicz O (1962) The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson\u2019s syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 203:560\u2013574","journal-title":"Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr"},{"issue":"11","key":"14_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00120-008-1843-x","volume":"47","author":"S Boy","year":"2008","unstructured":"Boy S, Seif C, Braun PM, J\u00fcnemann KP (2008) Botulinum toxin in the treatment of benign prostatic hyperplasia: an overview]. Urologe A 47(11):1465\u20131471","journal-title":"Urologe A"},{"issue":"10","key":"14_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23(10):1353\u20131360","journal-title":"Mov Disord"},{"key":"14_CR43","doi-asserted-by":"publisher","unstructured":"Chaddock J (2012) Transforming the domain structure of botulinum neurotoxins into novel therapeutics. doi:10.1007\/978-3-642-33570-9_13","DOI":"10.1007\/978-3-642-33570-9_13"},{"issue":"20","key":"14_CR8","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1001\/jama.296.20.2476","volume":"296","author":"DS Chertow","year":"2006","unstructured":"Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, Bernstein J, Marcus SM, Kumar S, Malecki J, Sobel J, Braden CR (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 296(20):2476\u20132479","journal-title":"JAMA"},{"issue":"3","key":"14_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/WNF.0b013e3181d479e0","volume":"33","author":"A Coban","year":"2010","unstructured":"Coban A, Matur Z, Hanagasi HA, Parman Y (2010) Iatrogenic botulism after botulinum toxin type A injections. Clin Neuropharmacol 33(3):158\u2013160","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"14_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/WNF.0b013e31804b1a0d","volume":"30","author":"BE Crowner","year":"2007","unstructured":"Crowner BE, Brunstrom JE, Racette BA (2007) Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. Clin Neuropharmacol 30(5):310\u2013313","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"14_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/WNF.0b013e3181f5329e","volume":"33","author":"BE Crowner","year":"2010","unstructured":"Crowner BE, Torres-Russotto D, Carter AR, Racette BA (2010) Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol 33(5):243\u2013247","journal-title":"Clin Neuropharmacol"},{"key":"14_CR12","first-page":"315","volume":"94","author":"D Dressler","year":"2004","unstructured":"Dressler D, Benecke R (2004) Autonomic side effects of botulinum toxin type B therapy. Adv Neurol 94:315\u2013320","journal-title":"Adv Neurol"},{"issue":"12","key":"14_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/mds.20625","volume":"20","author":"D Dressler","year":"2005","unstructured":"Dressler D, Lange M, Bigalke H (2005) Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord 20(12):1617\u20131619","journal-title":"Mov Disord"},{"issue":"4","key":"14_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","volume":"57","author":"KH Eisele","year":"2011","unstructured":"Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57(4):555\u2013565","journal-title":"Toxicon"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum toxin A therapy: neutralizing and non-neutralising antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"14_CR17","doi-asserted-by":"crossref","unstructured":"Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H (2012) Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins\u2013a single cohort 4-year follow-up study. BMJ Open 2(4) (4 Aug 2012)","DOI":"10.1136\/bmjopen-2011-000646"},{"issue":"12","key":"14_CR18","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","volume":"67","author":"J Jankovic","year":"2006","unstructured":"Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ (2006) Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67(12):2233\u20132235","journal-title":"Neurology"},{"key":"14_CR19","unstructured":"Jost WH (2007) Bildatlas der Botulinumtoxin-Injektion Der Medizinverlag 2007"},{"issue":"7","key":"14_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00702-004-0234-8","volume":"112","author":"WH Jost","year":"2005","unstructured":"Jost WH, Kohl A, Brinkmann S, Comes G (2005) Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 112(7):905\u2013913","journal-title":"J Neural Transm"},{"key":"14_CR21","unstructured":"Kerner J (1822) Das Fettgift oder die F etts\u00e4ure und ihre Wirkungen auf den thierischen Organismus T\u00fcbingen Cotta 1922"},{"issue":"7","key":"14_CR22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mus.880140711","volume":"14","author":"DJ Lange","year":"1991","unstructured":"Lange DJ, Rubin M, Greene PE, Kang UJ, Moskowitz CB, Brin MF, Lovelace RE, Fahn S (1991) Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 14(7):672\u2013675","journal-title":"Muscle Nerve"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","volume":"32","author":"O Lange","year":"2009","unstructured":"Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213\u2013218","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"14_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1600-0404.1977.tb01418.x","volume":"56","author":"H Lundh","year":"1977","unstructured":"Lundh H, Schiller HH, Elmqvist D (1977) Correlation between single fibre EMG jitter and endplate potentials studied in mild experimental botulinum poisoning. Acta Neurol Scand 56(2):141\u2013152","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"14_CR25","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.4317\/medoral.16.e96","volume":"16","author":"P Martos-D\u00edaz","year":"2011","unstructured":"Martos-D\u00edaz P, Rodr\u00edguez-Campo FJ, Bances-del Castillo R, Altura-Guill\u00e9n O, Cho-Lee GY, Mancha-de la-Plata M, Escorial-Hernandez V (2011) Lateral pterygoid muscle dystonia. A new technique for treatment with botulinum toxin guided by electromyography and arthroscopy. Med Oral Patol Oral Cir Bucal 16(1):e96\u2013e99","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"Suppl 4","key":"14_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1468-1331.2006.01652.x","volume":"13","author":"M Naumann","year":"2006","unstructured":"Naumann M, Albanese A, Heinen F, Molenaers G, Relja M (2006) Safety and efficacy of botulinum toxin type a following long-term use. Eur J Neurol 13(Suppl 4):35\u201340","journal-title":"Eur J Neurol"},{"issue":"4","key":"14_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00941758","volume":"235","author":"Z N\u00fcssgens","year":"1997","unstructured":"N\u00fcssgens Z, Roggenk\u00e4mper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235(4):197\u2013199","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"14_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaad.2008.12.042","volume":"61","author":"A Pickett","year":"2009","unstructured":"Pickett A, Mewies M (2009) Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol 61(1):149\u2013150","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"14_CR29","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0006-2952(00)00260-4","volume":"59","author":"J Purkiss","year":"2000","unstructured":"Purkiss J, Welch M, Doward S, Foster K (2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59(11):1403\u20131406","journal-title":"Biochem Pharmacol"},{"issue":"44","key":"14_CR30","doi-asserted-by":"publisher","first-page":"15650","DOI":"10.1523\/JNEUROSCI.2618-11.2011","volume":"31","author":"L Restani","year":"2011","unstructured":"Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M (2011) Evidence for anterograde transport and transcytosis of botulinum neurotoxin a (BoNT\/A). J Neurosci 31(44):15650\u201315659","journal-title":"J Neurosci"},{"issue":"5","key":"14_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/WNF.0b013e31815cba8a","volume":"31","author":"N Roche","year":"2008","unstructured":"Roche N, Schnitzler A, Gen\u00eat FF, Durand MC, Bensmail D (2008) Undesirable distant effects following botulinum toxin type a injection. Clin Neuropharmacol 31(5):272\u2013280","journal-title":"Clin Neuropharmacol"},{"key":"14_CR44","doi-asserted-by":"publisher","unstructured":"Rummel A (2012) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. doi:10.1007\/978-3-642-33570-9_4","DOI":"10.1007\/978-3-642-33570-9_4"},{"key":"14_CR32","unstructured":"Rummel A, Weil T, Gutscaits A (2005) Carrier for targeting nerve cells: toxogen GmbH, Hannoverfiled: 26th April 2005 Application no.: DE102005019302.1; PCT\/EP2006\/003896"},{"key":"14_CR45","doi-asserted-by":"publisher","unstructured":"Schiavo G, Bercsenyi K, Giribaldi F (2012) The Elusive Compass of Clostridial Neurotoxins: deciding when and where to go? doi:10.1007\/978-3-642-33570-9_5","DOI":"10.1007\/978-3-642-33570-9_5"},{"issue":"3","key":"14_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","volume":"103","author":"AB Scott","year":"1985","unstructured":"Scott AB, Kennedy RA, Stubbs HA (1985) Botulinum a toxin injection as a treatment for blepharospasm. Arch Ophthalmol 103(3):347\u2013350","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"14_CR34","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/444507","volume":"41","author":"J Sobel","year":"2005","unstructured":"Sobel J (2005) Botulism. Clin Infect Dis 41(8):1167\u20131173","journal-title":"Clin Infect Dis"},{"issue":"9","key":"14_CR35","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1172\/JCI63232","volume":"122","author":"E Somm","year":"2012","unstructured":"Somm E, Bonnet N, Martinez A, Marks PM, Cadd VA, Elliott M, Toulotte A, Ferrari SL, Rizzoli R, H\u00fcppi PS, Harper E, Melmed S, Jones R, Aubert ML (2012) A botulinum toxin\u2013derived targeted secretion inhibitor downregulates the GH\/IGF1 axis. J Clin Invest 122(9):3295\u20133306.","journal-title":"J Clin Invest"},{"issue":"1","key":"14_CR36","first-page":"219","volume":"20","author":"J Sonnemann","year":"2008","unstructured":"Sonnemann J, H\u00fcls I, Sigler M, Palani CD, le Hong TT, V\u00f6lker U, Kroemer HK, Beck JF (2008) Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. Oncol Rep 20(1):219\u2013224","journal-title":"Oncol Rep"},{"issue":"4","key":"14_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.febslet.2011.12.037","volume":"586","author":"J Strotmeier","year":"2012","unstructured":"Strotmeier J, Willjes G, Binz T, Rummel A (2012) Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586(4):310\u2013313","journal-title":"FEBS Lett"},{"issue":"2","key":"14_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenk\u00e4mper P (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type a products for the treatment of blepharospasm. J Neural Transm 118(2):233\u2013239","journal-title":"J Neural Transm"},{"issue":"2","key":"14_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00498587","volume":"292","author":"H Wiegand","year":"1976","unstructured":"Wiegand H, Erdmann G, Wellh\u00f6ner HH (1976) 125I-labelled botulinum a neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292(2):161\u2013165","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"14_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00500893","volume":"298","author":"H Wiegand","year":"1977","unstructured":"Wiegand H, Wellh\u00f6ner HH (1977) The action of botulinum a neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 298(3):235\u2013238","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"14_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/PL00004951","volume":"355","author":"K Wohlfarth","year":"1997","unstructured":"Wohlfarth K, G\u00f6schel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum a toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355(3):335\u2013340","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"14_CR42","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","volume":"46","author":"MA Wollmer","year":"2012","unstructured":"Wollmer MA, de Boer C, Kalak N, Beck J, G\u00f6tz T, Schmidt T, Hodzic M, Bayer U, Kollmann T, Kollewe K, S\u00f6nmez D, Duntsch K, Haug MD, Schedlowski M, Hatzinger M, Dressler D, Brand S, Holsboer-Trachsler E, Kruger TH (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 46(5):574\u2013581","journal-title":"J Psychiatr Res"}],"container-title":["Current Topics in Microbiology and Immunology","Botulinum Neurotoxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-33570-9_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:05:33Z","timestamp":1710497133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-33570-9_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9783642335693","9783642335709"],"references-count":44,"aliases":["10.1007\/978-3-662-45790-0_14","10.1007\/978-3-662-45790-0_14"],"URL":"https:\/\/doi.org\/10.1007\/978-3-642-33570-9_14","relation":{},"ISSN":["0070-217X"],"issn-type":[{"value":"0070-217X","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"14 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}